Neurology · Anxiolytic
The FDA's approval status for Lupin's Diazepam ANDA220365 is significant as it positions Lupin to enhance its competitive standing in the anxiolytic market. This development necessitates careful monitoring of market dynamics and potential shifts in pricing strategies as Lupin prepares for market entry.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/30/2026, 6:30:58 AM
Assessment confidence: 61% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's approval status for Lupin's Diazepam ANDA220365 is significant as it positions Lupin to enhance its competitive standing in the anxiolytic market. This development necessitates careful monitoring of market dynamics and potential shifts in pricing strategies as Lupin prepares for market entry. Regulatory context from FDA (FDA AP — DIAZEPAM (ORIG)) supports the near-term read. Assessment grounded in 14 ranked evidence items (5 high-relevance).
Portfolio teams should assess the impact of this approval on market share and pricing strategies in the anxiolytic segment. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Neurology · Anxiolytic, 3 regulatory and 3 competitive items passed relevance filtering for Lupin.
The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN. This approval may enhance Lupin's position in the anxiolytic market, competing with established players.
Regulatory risk is concentrated around FDA AP — DIAZEPAM (ORIG) (FDA). Entity match (lupin); Regulatory pathway relevance (nda). While the approval status indicates progress, the final approval and subsequent market launch will be critical to assess compliance and market readiness.
FDA AP — DIAZEPAM (ORIG)
FDAhigh relevance
Entity match (lupin); Regulatory pathway relevance (nda)
FDA document
View sourceAdvancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceRare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View sourceThe Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRelationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMenstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceDynamic Auditory Cueing for Spatial Neglect in Stroke
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceNeurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourcePhysical and Behavioral Traits of Overweight and Obese Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceRoche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Novartishigh relevance
Sponsor/company relevance (Novartis)
FDA document
View sourceFDA Grants Priority Review for Otsuka's Simtriyo (Centanafadine)
Humanexa Signalsmedium relevance
Moderate corpus alignment
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's approval status for Lupin's Diazepam ANDA220365 is significant as it positions Lupin to enhance its competitive standing in the anxiolytic market. This development necessitates careful monitoring of market dynamics and potential shifts in pricing strategies as Lupin prepares for market entry.
Lupin's entry into the anxiolytic market with Diazepam could disrupt existing market shares, particularly against established competitors, potentially affecting revenue streams.
While the approval status indicates progress, the final approval and subsequent market launch will be critical to assess compliance and market readiness.
Monitor for the final approval and market launch timelines for Diazepam.
Track for follow-up milestones; no immediate action required.